quinacrine

Small moleculeexperimental

Quinacrine was initially developed as an anti-malarial drug marketed under the name Atabrine. Also it was approved for the teratment of ascites, however it was wothdrawn for both indication in 1995 and 2003, respectively. The drug is also used for the treatment of giardiasis, lupus, rheumatoid arthritis, refractory pulmonary effusion and pneumothorax, induce female sterilization etc. Proposed mechanisms of action include DNA intercalation interference with RNA transcription and translation, inhibition of succinate oxidation interference with electron transport, inhibition of cholinesterase, and inhibitor of phospholipase. — NCATS

Clinical trial activity

6 trials · 7 clinical orgs · 0 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started Jun 1, 2004 (NCT00104663)

Timeline

2000s

Jan 1, 2005
Earliest Phase 2 Sponsor(trial)

2010s

Jan 1, 2013
Earliest Phase 1 Sponsor(trial)

Indications

Studied for

Mechanism of action

Unspecified targetUnclear
unclear

Chemistry & pharmacology

Loading structure…

SMILES

O.O.Cl.Cl.CCN(CC)CCCC(C)NC1=C2C=C(OC)C=CC2=NC3=CC(Cl)=CC=C13

Mol. weight: 508.909 g/mol
Lipinski Ro5: 1 violation(s)
Rule of 3: No
Chirality: Racemic Mixture
Inorganic: No
Polymer: No

Oral

Parenteral

Topical

Sources

Also known as

2-methoxy-6-chloro-9-diethylaminopentylaminoacridine
2-methoxy-6-chloro-9-diethylaminopentylaminoacridine
3-chloro-7-methoxy-9-(1-methyl-4-diethylaminobutylamino)acridine
3-chloro-7-methoxy-9-(1-methyl-4-diethylaminobutylamino)acridine
6-chloro-9-((4-(diethylamino)-1-methylbutyl)amino)-2-methoxyacridine
6-chloro-9-((4-(diethylamino)-1-methylbutyl)amino)-2-methoxyacridine
acrinamine
acriquine
atabrine
atebrine
atebrine
gnf-pf-5448
gnf-pf-5448
mepacrine
mepacrine
mepacrine
mepacrine
mepacrine
mepacrine
n4-(6-chloro-2-methoxy-9-acridinyl)-n1,n1-diethyl-1,4-pentanediamine
n4-(6-chloro-2-methoxy-9-acridinyl)-n1,n1-diethyl-1,4-pentanediamine
quinacrin
quinacrin
quinacrin
quinacrin
quinacrin
quinacrin
quinacrine
quinacrine
quinacrine
quinacrine
quinacrine
quinacrine
quinacrine
quinacrine dihydrochloride
quinacrine dihydrochloride hydrate
quinacrine hcl
quinacrine hydrochloride

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT01844076	Phase 1/Phase 2 (Phase 2)	Mar 1, 2014	Pennsylvania State University
NCT01839955	Phase 1	Sep 1, 2013	Case Western Reserve University
NCT00574483	Phase 2	Nov 1, 2007	Cleveland BioLabs
NCT00417274	Phase 2	Dec 1, 2006	Cleveland BioLabs, University of Chicago
NCT00183092	Phase 2	Apr 1, 2005	National Institute on Aging (NIA), University of California, San Francisco
NCT00104663	N/A	Jun 1, 2004	Medical Research Council

Showing 6 of 6 trials

Page 1 / 1

Organizations

Research & Development (7)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Cleveland BioLabs	For profit	2	2	1	2006
Case Western Reserve University	Academic/Hospital	1	1	1	2013
Medical Research Council	Government	1	1	1	2004
National Institute on Aging (NIA)	Government	1	0	1	2005
Pennsylvania State University	Academic/Hospital	1	1	1	2014
University of California, San Francisco	Academic/Hospital	1	1	1	2005
University of Chicago	Academic/Hospital	1	0	1	2006

7 organizations

Page 1 / 1